8-K/A - Intellia Therapeutics, Inc. (0001652130) (Filer)
Published . Updated .
Key takeaways
- 8-K/A - Intellia Therapeutics filed an 8-K with the SEC on Nov 13 (a notice of a material company event).
- Exposed: NTLA
- Market reaction: price tracking starts with the next trading session.
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
8-K/A - Intellia Therapeutics filed an 8-K with the SEC on Nov 13 (a notice of a material company event).
Directly affected
- NTLA Intellia Therapeutics-14.7% 9d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Intellia Therapeutics belongs to, so it often moves with news about it.
- IDXX IDEXX Laboratories+34.6% 16d
IDEXX Laboratories is a peer of Intellia Therapeutics in in vitro and in vivo diagnostic substances; rivals often move on the same news.
- LNTH Lantheus Holdings+1.3% 30d
Lantheus Holdings is a peer of Intellia Therapeutics in in vitro and in vivo diagnostic substances; rivals often move on the same news.
- NEOG Neogen-6.5% 30d
Neogen is a peer of Intellia Therapeutics in in vitro and in vivo diagnostic substances; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NTLA | +24.74% | +17.63% | base | after close | after close | after close | after close |
| XLV | -0.28% | +0.04% | base | after close | after close | after close | after close |
| IDXX | +0.39% | -0.28% | base | after close | after close | after close | after close |
| LNTH | -0.59% | -0.01% | base | after close | after close | after close | after close |
| NEOG | +7.48% | +3.29% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Filed: 2026-11-13 AccNo: 0001193125-26-460948 Size: 29 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Source: sec-edgar
Intellia Therapeutics (NTLA) since this story, compared with the market
| Company | When | Move | Status |
|---|---|---|---|
| IDXX | three days earlier | -0.28% | final price |
| IDXX | five days earlier | +0.39% | final price |
| LNTH | three days earlier | -0.01% | final price |
| LNTH | five days earlier | -0.59% | final price |
| NEOG | three days earlier | +3.29% | final price |
| NEOG | five days earlier | +7.48% | final price |
| Intellia Therapeutics (NTLA) | three days earlier | +17.63% | final price |
| Intellia Therapeutics (NTLA) | five days earlier | +24.74% | final price |
| XLV | three days earlier | +0.04% | final price |
| XLV | five days earlier | -0.28% | final price |
Congressional trades in the stocks in this story
- Rep. Rohit Khanna bought Idexx Laboratories (IDXX) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 49 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Idexx Laboratories (IDXX) (held by a dependent child), worth $15,001 - $50,000 on 11 Sep 2026. That is 63 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Idexx Laboratories (IDXX) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 70 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Gilbert Cisneros sold Lantheus Holdings (LNTH), worth $1,001 - $15,000 on 15 Oct 2026. That is 29 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Gilbert Cisneros sold Lantheus Holdings (LNTH), worth $1,001 - $15,000 on 14 Oct 2026. That is 30 days before publication. Filed 10 Nov 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who is named in “8-K/A - Intellia Therapeutics, Inc. (0001652130) (Filer)”
Companies tied to this story
- NTLA Intellia Therapeutics
For “8-K/A - Intellia Therapeutics, Inc. (0001652130) (Filer),” Intellia Therapeutics (NTLA) is linked, with no stored direction, high confidence. Reason on file: SEC 8-K filing -> direct issuer disclosure -> NTLA
How “8-K/A - Intellia Therapeutics, Inc. (0001652130) (Filer)” reaches Intellia Therapeutics (NTLA)
Intellia Therapeutics (NTLA) is the company in “8-K/A - Intellia Therapeutics, Inc. (0001652130) (Filer),” the 13 Nov 2026 this story story.
The link for Intellia Therapeutics (NTLA) is this: SEC 8-K filing -> direct issuer disclosure -> NTLA
The price range for Intellia Therapeutics (NTLA), and the dates in the story
NTLA traded between 10.46 and 13.21 across 9 sessions. The latest close on file is 10.55.
What the saved facts support for Intellia Therapeutics (NTLA)
14 out of 100
“8-K/A - Intellia Therapeutics, Inc. (0001652130) (Filer)” scores 14 out of 100. The score uses 1 sources, and 1 linked companies.